Back to Results
First PageMeta Content
Antianginals / Benzazepines / Ivabradine / Lactams / Servier / Heart diseases / Heart rate / Angina pectoris / Heart failure / Organic chemistry / Chemistry / Cardiology


Document Date: 2014-10-01 21:56:22

Open Document

File Size: 105,01 KB

Share Result on Facebook

City

Trial / /

Company

AEs / Servier Laboratories (Australia) Pty Ltd / Cox / The PBAC / Restrictions Working Group / ITT / /

Country

Australia / /

Currency

USD / /

Event

FDA Phase / Reorganization / /

IndustryTerm

heart failure therapy / Treatment of coronary artery disease / treatment of symptomatic systolic heart failure / medical management / Treatment of chronic heart failure / chronic heart failure treatment / Treatment of symptomatic chronic heart failure / The Systolic Heart Failure Treatment / /

MedicalCondition

severe chronic heart failure / valvular heart disease / hypertension / cancer / respiratory failure / chronic heart failure / Proposed Therapy Chronic heart failure / chronic stable angina / concurrent disease / chronic / dysfunction / nausea / symptomatic chronic heart failure / ischaemic heart disease / atherosclerotic coronary artery disease / persistent cough / ventricular systolic dysfunction / fatigue / PBAC’s View Authority Required Symptomatic systolic heart failure / Heart Failure / systolic heart failure / optimal standard chronic heart failure treatment / bradycardia / optimal heart failure / coronary artery disease / angina / symptomatic systolic heart failure / renal failure / idiopathic dilated cardiomyopathy / /

Position

nurse / First author / representative / /

Product

Ivabradine / atenolol / sponsor / /

Technology

author Ivabradine trials vs placebo Protocol / /

SocialTag